ERBB2 and breast cancer: Toxicity has been tested in a phase 1b clinical trial for HR+ HER2- breast cancer to test the safety of the drugs, resulting in a manageable safety profile with no observed interactions between the two drugs [51], which is a promising outcome since both drugs have serious, but manageable side effects alone.